Structural: Selected Topics in TAVI | SOLACI-SOCIME 2022

✔️ MITRAL VALVE Session

✔️ SOLACI-SOCIME 2022 Scientific Session

👨‍🏫 Content:

00:09 – Welcoming Words – Dr. Jorge Cortés (MEX)
01:16 – TAVR for aortic regurgitation – Dr. Raj Makkar (USA)
18:53 – Reduced leaflet motion: the real clinical impact – Dr. Ole de Backer (DNK)
34:17 – TAVR in bicuspid aortic valve: Clinical evidence – Dr. Raj Makkar (USA)


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Advances in Structural Intervention – SOLACI-SOCIME 2022

✔️ Advances in Structural Intervention - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 - Palabras de Bienvenida - Dr. Guering Eid-Lidt (MEX)...

Endovascular Treatment of Femoropopliteal Segment – SOLACI-SOCIME 2022

✔️ Endovascular Treatment of Femoropopliteal Segment - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 - How Palabras de bienvenida - Dr. Luis Virgen...

Pulmonary Valve – SOLACI-SOCIME 2022

✔️ Pulmonary Valve - SOLACI-SOCIME 2022 ✔️ SOLACI-SOCIME 2022 Scientific Sessions 👨‍🏫 Contents: 00:10 - How to select the type of THV in pulmonary valve...

Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022

✔️ Complex PCI: Distal Left Main Coronary Artery - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session.  👨‍🏫 Contents: 00:13 - Welcoming words - Dr. Álvaro...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...